{
  "title": "Paper_482",
  "abstract": "pmc Medeni Med J Medeni Med J 3865 medenmedj Medeniyet Medical Journal 2149-2042 2149-4606 Istanbul Medeniyet University PMC12478624 PMC12478624.1 12478624 12478624 41019760 10.4274/MMJ.galenos.2025.63838 1 Review Exploring the Link between DNA Hypermethylation and HPV in Salivary Gland Tumors Tükürük Bezi Tümörlerinde DNA Hipermetilasyonu ve HPV Arasındaki Bağlantının Araştırılması https://orcid.org/0009-0005-3018-7421 MEER Anzila 1 https://orcid.org/0000-0001-5369-2707 SULONG Sarina 2 https://orcid.org/0000-0001-8026-3078 ZIN Anani Aila MAT 3 https://orcid.org/0000-0002-2465-6421 MOHAMUD Rohimah 4 https://orcid.org/0000-0002-2367-1814 LAZIM Norhafiza MAT 1 norhafiza@usm.my 1 2 3 4 9 2025 29 9 2025 40 3 497795 187 192 20 5 2025 01 8 2025 29 09 2025 30 09 2025 30 09 2025 Copyright© 2025 The Author. Published by Galenos Publishing House on behalf of Istanbul Medeniyet University Faculty of Medicine. 2025 Medeniyet Medical Journal https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the Creative Commons AttributionNonCommercial 4.0 International (CC BY-NC 4.0) License. ABSTRACT Salivary gland tumors (SGTs) pose considerable diagnostic and treatment challenges due to their heterogeneous nature, diverse histogenesis, and unpredictable clinical outcomes. Benign tumors exhibit a known recurrence rate, whereas malignant tumors are associated with a poor prognosis and a low recovery rate. Nonetheless, despite the growing body of research, there is insufficient evidence to establish a link between SGTs, human papilloma virus (HPV) infection, and the hypermethylation of tumor suppressor genes. The aim of this study is to elucidate the relationship between DNA hypermethylation and HPV in SGTs, elucidate the role of DNA hypermethylation in HPV-associated SGTs, thereby offering insights into novel diagnostic, and prognostic markers. As epigenetic alterations significantly contribute to the development of carcinogenesis, addressing these epigenetic alterations may help in early treatment plans and early detection of SGTs. ÖZ Tükürük bezi tümörleri (SGT’ler), heterojen yapıları, çeşitli histogenezleri ve öngörülemez klinik sonuçları nedeniyle tanı ve tedavi açısından önemli zorluklar oluşturmaktadır. Benign tümörlerin belirli bir oranda nüksettiği bilinmekteyken, malign tümörler kötü prognoz ve düşük iyileşme oranıyla ilişkilidir. Bununla birlikte, artan araştırmalara rağmen, SGT’ler, insan papilloma virüsü (HPV) enfeksiyonu ve tümör baskılayıcı genlerin (TSG’ler) hipermetilasyonu arasındaki bağlantıyı kanıtlayacak yeterli kanıt bulunmamaktadır. Bu çalışmanın amacı, SGT’lerde DNA hipermetilasyonu ve HPV arasındaki ilişkiyi aydınlatmak, HPV ile ilişkili SGT’lerde DNA hipermetilasyonunun rolünü açıklamak ve böylece yeni tanı ve prognostik belirteçler hakkında bilgi sağlamaktır. Epigenetik değişiklikler karsinogenez gelişimine önemli ölçüde katkıda bulunduğundan, bu epigenetik değişikliklerin ele alınması, SGT’lerin erken tedavi planları ve erken teşhisinde yardımcı olabilir. DNA hypermethylation epigenetics salivary gland tumors human papilloma virus tumor suppressor genes DNA hipermetilasyonu epigenetik tükürük bezi tümörleri insan papilloma virüsü tümör baskılayıcı genler pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes INTRODUCTION Salivary gland tumors (SGTs) are rare and heterogeneous in nature, have diverse histogenesis, and show unpredictable clinical outcomes. World Health Organization (WHO) Global Cancer Observatory reported 53,083 new cases diagnosed worldwide in 2020, with an incidence rate of 0.56 and a death rate of 0.23 per 100,000 individual-years 1 th th 2 3 Importance of Epigenetic Modifications in SGTs Epigenetics refers to heritable changes in gene expression that occur independently of alterations to the DNA sequence 4 5 6 7 8 9 10 11 12 13 14 Epidemiology and Categorization of SGT SGTs comprise a varied collection of benign and malignant neoplasms distinguished by diverse, occasionally overlapping, unpredictable, and histological characteristics. Numerous molecular alterations are also observed 15 16 17 18 19 The histopathological variation among SGTs, which includes many subtypes categorized by WHO 17 20 21 22 23 24 25 5 The Implications of Hypermethylation in SGTs and Tumor Suppressor Gene Silencing Hypermethylation leads to the silencing of a substantial number of TSGs which are essential in controlling the hallmarks of carcinogenesis in human cancers 26 27 28 29 30 31 14 32 Research Connecting DNA Hypermethylation in SGTs Prognosis DNA hypermethylation may function as a significant biomarker for monitoring tumor growth, forecasting malignancy, and offering prognostic information 33 34 35 36 37 Table 1 Overview of Human Papilloma Virus (HPV) Infection in Tumorigenesis and Its Epigenetic Role in SGT: Contemporary Evidence Human papilloma virus (HPV) is a small, circular, double-stranded DNA virus that primarily targets cutaneous and mucosal epithelial tissues. Although the complete mechanism of HPV infection remains incompletely understood, the widely accepted model suggests that the virus gains entry through micro-abrasions in the epithelial basement membrane. Following endocytosis, the viral genome is transported to the nucleus, where replication and transcription are initiated using host cellular machinery. The HPV genome consists of eight open reading frames: six early genes (E1, E2, E4, E5, E6, and E7) and two late genes (L1 and L2). The early genes are chiefly involved in viral replication, transcription, and modulation of host cellular pathways, while the late genes encode structural proteins essential for capsid formation. Among the early genes, E6 and E7 have been extensively studied for their oncogenic potential, particularly their ability to disrupt cell cycle regulation and inhibit tumor suppressor proteins such as p53 and Rb. The late genes, L1 and L2, encapsulate the replicated viral genome into icosahedral virions, which are eventually released through the natural process of epithelial desquamation 41 42 43 44 The underlying causes of SGTs remain largely undefined, though various risk factors such  as radiation, silica dust rubber chemicals, and viruses including Epstein-Barr virus and HPV are believed to contribute to their development and progression. Most tumors, however, do not have a discernible etiology 45 46 47 48 Possibility of Integrated SGTs Biomarker Strategies Various diagnostic methodologies are  being investigated to enhance the diagnosis and treatment planning for SGTs. The examination of morphology parameters, which include inflammatory biomarkers, such as the systemic immune-inflammation index, the systemic inflammation response index, the platelet-to-lymphocyte ratio, and the neutrophil-to-lymphocyte ratio, and radiomic features obtained from imaging techniques such as nuclear magnetic resonance image sequences and histopathology slides, is conducted as part of prospective diagnostic targets 49 50 51 CONCLUSION We conclude that studies establishing correlations, conducting comprehensive clinical trials, and examining the predictive and therapeutic relevance of hypermethylation and SGTs are unclear and vary across study populations. This could be due to multiple reasons, such as geographical locations, environmental factors, and delayed diagnosis, where two-thirds of cases are identified at stage 3 or 4 and the lack of molecular indicators to forecast tumor behavior and facilitate patient stratification for customized treatment 52 . 16 Author Contributions: Conflict of Interest: Financial Disclosure: References 1 World Health Organization. Salivary glands cancer fact sheet. Lyon: International Agency for Research on Cancer; 2022 [cited 2025 Sep 25]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/2-Salivary-glands-fact-sheet.pdf. 2 Bray F Laversanne M Sung H Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024 74 3 229 63 10.3322/caac.21834 38572751 3 Locati LD Ferrarotto R Licitra L Current management and future challenges in salivary glands cancer. Front Oncol 2023 13 1264287 37795454 10.3389/fonc.2023.1264287 PMC10546333 4 Waddington CH The epigenotype. 1942. Int J Epidemiol 2012 41 1 10 3 10.1093/ije/dyr184 22186258 5 Xia L Hu Y Gu T Wang L Tian Z Promoter hypermethylation may contribute to Ecadherin repression in the human salivary carcinoma ex pleomorphic adenoma. Int J Oncol 2018 52 496 504 29207084 10.3892/ijo.2017.4210 6 Kong X Chen J Xie W Defining UHRF1 domains that support maintenance of human colon cancer DNA methylation and oncogenic properties. Cancer Cell 2019 35 4 633 48 10.1016/j.ccell.2019.03.003 30956060 PMC6521721 7 Sharma S Kelly TK Jones PA Epigenetics in cancer. Carcinogenesis 2010 31 1 27 36 10.1093/carcin/bgp220 19752007 PMC2802667 8 Manou M Kanakoglou DS Loupis T Role of histone deacetylases in the pathogenesis of salivary gland tumors and therapeutic targeting options. Int J Mol Sci 2023 24 10038 37373187 10.3390/ijms241210038 PMC10298439 9 Dupont C Armant DR Brenner CA Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med 2009 27 5 351 7 10.1055/s-0029-1237423 19711245 PMC2791696 10 Ilić Dimitrijević I Löning T Falk M Incidence and clinical relevance of t (11; 19) translocation in salivary gland mucoepidermoid carcinoma. Genetika 2014 46 601 10 11 Šteiner P Andreasen S Grossmann P Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands. Virchows Arch 2018 473 4 471 80 10.1007/s00428-018-2349-6 29619555 12 Vila L Liu H Al-Quran SZ Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol 2009 22 1296 302 19617878 10.1038/modpathol.2009.95 PMC3746033 13 Majewska H Gorczyński A Czapiewski P ALK alterations in salivary gland carcinomas. Virchows Arch 2021 478 5 933 41 10.1007/s00428-020-02971-w 33237469 PMC8099847 14 Nikolic N Carkic J Ilic Dimitrijevic I P14 methylation: an epigenetic signature of salivary gland mucoepidermoid carcinoma in the Serbian population. Oral Surg Oral Med Oral Pathol Oral Radiol 2018 125 1 52 8 10.1016/j.oooo.2017.09.013 29079368 15 Young A, Okuyemi OT. Malignant salivary gland tumors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Sep 25]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555986/ 33079504 16 Colombo E Van Lierde C Zlate A Salivary gland cancers in elderly patients: challenges and therapeutic strategies. Front Oncol 2022 12 1032471 36505842 10.3389/fonc.2022.1032471 PMC9733538 17 Cunha JLS Hernandez-Guerrero JC de Almeida OP Soares CD Mosqueda-Taylor A Salivary gland tumors: a retrospective study of 164 cases from a single private practice service in Mexico and literature review. Head Neck Pathol 2021 15 2 523 31 10.1007/s12105-020-01231-2 33044721 PMC8134594 18 Valstar MH de Ridder M van den Broek EC Salivary gland pleomorphic adenoma in the Netherlands: a nationwide observational study of primary tumor incidence, malignant transformation, recurrence, and risk factors for recurrence. Oral Oncol 2017 66 93 9 10.1016/j.oraloncology.2017.01.004 28249655 19 Kane AC Ryan WR Cognetti D Salivary gland neoplasms. Curr Otorhinolaryngol Rep 2020 8 298 303 20 Sowa P Goroszkiewicz K Szydelko J A review of selected factors of salivary gland tumour formation and malignant transformation. Biomed Res Int 2018 2018 2897827 10.1155/2018/2897827 30155477 PMC6092996 21 Holtzman A Morris CG Amdur RJ Dziegielewski PT Boyce B Mendenhall WM Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma. Acta Oncol 2017 56 3 484 9 10.1080/0284186X.2016.1253863 27846763 22 Sentani K Ogawa I Ozasa K Characteristics of 5015 salivary gland neoplasms registered in the Hiroshima tumor tissue registry over a period of 39 years. J Clin Med 2025 8 566 10.3390/jcm8050566 PMC6571736 31027324 23 Dantas AN Morais EF Macedo RA Tinôco JM Morais Mde L Clinicopathological characteristics and perineural invasion in adenoid cystic carcinoma: a systematic review. Braz J Otorhinolaryngol 2015 81 3 329 35 10.1016/j.bjorl.2014.07.016 25962319 PMC9452271 24 Lewis AG Tong T Maghami E Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol Clin North Am 2016 49 2 343 80 10.1016/j.otc.2015.11.001 27040585 25 Pisharodi L Mammary analog secretory carcinoma of salivary gland: cytologic diagnosis and differential diagnosis of an unreported entity. Diagn Cytopathol 2013 41 3 239 41 10.1002/dc.21766 22549921 26 Luczak MW Jagodziński PP The role of DNA methylation in cancer development. Folia Histochem Cytobiol 2006 44 3 143 54 16977793 27 Dos Santos ES Ramos JC Normando AGC Mariano FV Paes Leme AF Epigenetic alterations in salivary gland tumors. Oral Dis 2020 26 8 1610 8 10.1111/odi.13253 31829479 28 Wang LH Wu CF Rajasekaran N Shin YK Loss of tumor suppressor gene function in human cancer: an overview. Cell Physiol Biochem 2018 51 2647 93 30562755 10.1159/000495956 29 Rodríguez-Paredes M Esteller M Cancer epigenetics reaches mainstream oncology. Nat Med 2011 17 3 330 9 10.1038/nm.2305 21386836 30 Bouras E Karakioulaki M Bougioukas KI Aivaliotis M Tzimagiorgis G Chourdakis M Gene promoter methylation and cancer: an umbrella review. Gene 2019 710 333 40 10.1016/j.gene.2019.06.023 31202904 31 Nikolic N Carkic J Jacimovic J Methylation of tumour suppressor genes in benign and malignant salivary gland tumours: a systematic review and meta-analysis. Epigenetics 2022 17 12 1661 76 10.1080/15592294.2022.2052426 35287544 PMC9620987 32 Dawson MA Kouzarides T Cancer epigenetics: from mechanism to therapy. Cell 2012 150 1 12 27 10.1016/j.cell.2012.06.013 22770212 33 Koutsimpelas D Pongsapich W Heinrich U Mann S Mann WJ Brieger J Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. Oncol Rep 2012 27 4 1135 41 10.3892/or.2012.1624 22246327 PMC3583513 34 Castilho RM Squarize CH Almeida LO Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int J Mol Sci 2017 18 7 1506 10.3390/ijms18071506 28704968 PMC5535996 35 Manou M Kanakoglou DS Loupis T Role of histone deacetylases in the pathogenesis of salivary gland tumors and therapeutic targeting options. Int J Mol Sci 2023 24 10038 37373187 10.3390/ijms241210038 PMC10298439 36 Rapado-González Ó Martínez-Reglero C Salgado-Barreira Á Salivary dna methylation as an epigenetic biomarker for head and neck cancer. Part II: a cancer risk meta-analysis. J Pers Med 2021 11 606 34206840 10.3390/jpm11070606 PMC8304899 37 Williams MD Chakravarti N Kies MS Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 2006 12 24 7353 8 10.1158/1078-0432.ccr-06-1272 17189407 38 Yin XL Ha PK Genetic alterations in salivary gland cancers. Cancer 2016 122 12 1822 31 10.1002/cncr.29890 26928905 PMC5783696 39 Bell A Bell D Weber RS El-Naggar AK CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. Cancer 2011 117 13 2898 909 10.1002/cncr.25818 21692051 PMC3123690 40 Skálová A Hyrcza MD Leivo I Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands. Head Neck Pathol 2022 16 1 40 53 10.1007/s12105-022-01420-1 35312980 PMC9018948 41 Jensen JE Becker GL Jackson JB Rysavy MB Human papillomavirus and associated cancers: a review. Viruses 2024 16 5 680 10.3390/v16050680 38793561 PMC11125882 42 Workowski KA Bachmann LH Chan PA Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021 70 4 1 187 10.15585/mmwr.rr7004a1 PMC8344968 34292926 43 Cossellu G Fedele L Badaoui B Prevalence and concordance of oral and genital HPV in women positive for cervical HPV infection and in their sexual stable partners: an Italian screening study. PLoS One 2018 13 10 e0205574 10.1371/journal.pone.0205574 30335788 PMC6193646 44 Moscicki AB Schiffman M Burchell A Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012 30 Suppl F24 33 10.1016/j.vaccine.2012.05.089 23199964 PMC3700362 45 American Head and Neck Society. Salivary gland tumors – What you need to know [Internet]. n.d. [cited 2024 Dec 29]. Available from: https://www.ahns.info/salivary-gland/sg-tumors-what-you-need-to-know/ 46 Sen P Ganguly P Ganguly N Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer. Oncol Lett 2018 15 1 11 22 10.3892/ol.2017.7292 29285184 PMC5738689 47 Hung SH Yang TH Lee HC Lin HC Chen CS Association of salivary gland cancer with human papillomavirus infections. Eur Arch Otorhinolaryngol 2025 282 1 403 8 10.1007/s00405-024-08906-4 39179913 48 Grünewald I Vollbrecht C Meinrath J Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget 2015 6 20 18224 37 10.18632/oncotarget.4015 26053092 PMC4627247 49 Committeri U Barone S Salzano G Support tools in the differential diagnosis of salivary gland tumors through inflammatory biomarkers and radiomics metrics: a preliminary study. Cancers (Basel) 2023 15 1876 36980760 10.3390/cancers15061876 PMC10047378 50 Baxi V Edwards R Montalto M Saha S Digital pathology and artificial intelligence in translational medicine and clinical practice. Mod Pathol 2022 35 1 23 32 10.1038/s41379-021-00919-2 34611303 PMC8491759 51 De Felice F Valentini V De Vincentiis M Prediction of recurrence by machine learning in salivary gland cancer patients after adjuvant (chemo) radiotherapy. In Vivo 2021 35 3355 60 34697169 10.21873/invivo.12633 PMC8627718 52 Morandi L Gissi D Tarsitano A CpG location and methylation level are crucial factors for the early detection of oral squamous cell carcinoma in brushing samples using bisulfite sequencing of a 13-gene panel. Clin Epigenetics 2017 9 85 28814981 10.1186/s13148-017-0386-7 PMC5558660 Table 1. Highly prevalent genetic alterations in benign and malignant salivary gland tumor.   No   Tumor type   Genetic alterations/oncogenes   Methylation pattern   Prevalence   Key role in tumorigenesis   Ref  1  MEC  MECT1-MAML2, EGFR, HER2  Hypermethylation and genetic translocations  40-90%  Methylation status linked to tumor progression  ( 38  2  AdCC  EN1, FOXE1, TBX4, PITX1  Hypermethylation of TSGs  ~ 80%  Methylation status linked to tumorigenesis  ( 39  3  SC  ETV6-NTRK3 fusion  Showed unmethylated results  > 90%  No molecular alteration  ( 40  4  AciCC  NR4A3 fusion, RASSF1  Hypermethylation  86%  Methylation status linked to tumorigenesis  ( 37  5  MSA  MEF2C-SS18 fusion  NA  > 90%  NA  ( 40  6  MAC  AKT1 E17K mutations  NA  100%  Mutant  ( 40  7  Ca ex-Pa  PLAG1 fusions  NA  73%  Amplification  ( 40  8  PA  PLAG1 fusions, MGMT, DAPK  Hypermethylation pattern  > 50%  Methylation status partially linked to tumorigenesis  ( 37  9  BCA  CTNNB1  NA  37-80%  Mutant  ( 40  10  SP  BRAF V600E  NA  50%-100%  Mutant  ( 40 MEC: Mucoepidermoid carcinoma, AdCC: Adeniod cyctic carcinoma, SC: Secretory carcinoma, AciCC: Acinic cell carcinoma, MSA: Microsecretory adenocarcinoma, MAC: Mucinous adenocarcinoma, Ca ex-Pa: Carcinoma ex pleomorphic adenoma, PA: Pleomorphic adenoma, BCA: Basal cell adenoma, SP: Sialadenoma papilliferum, NA: Not applicable ",
  "metadata": {
    "Title of this paper": "CpG location and methylation level are crucial factors for the early detection of oral squamous cell carcinoma in brushing samples using bisulfite sequencing of a 13-gene panel.",
    "Journal it was published in:": "Medeniyet Medical Journal",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12478624/"
  }
}